



30

1632

CERTIFICATE OF MAILING

PATENT  
Attorney Docket No.: R-741

hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA. 22313-1450

On 10/23/03

DELTAGEN, INC.

By: Don Mixon  
Don Mixon

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

KEITH D. ALLEN

Application No.: 10/005,220

Filed: December 4, 2001

For: Transgenic Mice Containing RPTPB Tyrosine Phosphatase Gene Disruptions

Examiner: Unassigned

Art Unit: Unassigned

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER 37  
CFR §1.97 and §1.98

Assistant Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313 -1450

Sir:

The references cited on attached Form PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Each item of information contained in the information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.


While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR § 1.56, it is not intended to constitute an admission that

any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR § 1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR § 1.98 and MPEP § 609 and the Examiner is respectfully requested to consider the listed references.


The Commissioner is hereby authorized to charge our Deposit Account No. 50-1271 for any fees required in connection with the filing of this Information Disclosure Statement. In particular, in the event that an Office Action has crossed in the mail with this Information Disclosure Statement, the Commissioner is authorized to charge the above-named deposit account for any fees required pursuant to CFR § 1.17(p) or § 1.17(i)(1).

Respectfully submitted,

  
\_\_\_\_\_  
Kelly L. Quast, Reg. No. 52,141

DELTAGEN, INC.  
1031 Bing Street  
San Carlos, CA 94070  
Tel: 650-569-5100  
Fax: 650-569-5280

KLQ/dxm



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2**Complete if Known**

Applicati n Numb r	10/005,220
Filing Date	December 4, 2001
First Named Invent r	ALLEN
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	R-741

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AA	S. HARROCH, et al., "No Obvious Abnormality in Mice Deficient in Receptor Protein Tyrosine Phosphatase $\beta$ " <i>Molecular and Cellular Biology</i> , Vol. 20(20) October 2000, pp.7706-7715	
	AB	TAKAFUMI SHINTANI, et al., "Neurons and well as astrocytes express proteoglycan-type protein tyrosine phosphatase $\zeta$ RPTP $\beta$ : analysis of mice in which the <i>PTP<math>\zeta</math>RPTP<math>\beta</math></i> gene was replaced with the <i>LacZ</i> gene" Vol. 247, (1998) pp. 135-138	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Unsaved Document



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Applicant Number	10/005,220
Filing Date	December 4, 2001
First Named Inventor	ALLEN
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	R-741

Sheet 2 of 2**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	AC	WO	00/06712	A2	02/10/00	Merck Frosst Ca. Inc.		

Examiner  
SignatureDate  
Considered

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Unsaved Document